Benjamin MS - Recursion Pharmaceuticals Chief Officer

RXRX Stock  USD 7.46  0.81  9.79%   

Insider

Benjamin MS is Chief Officer of Recursion Pharmaceuticals
Age 41
Address 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101
Phone385 269 0203
Webhttps://www.recursion.com

Recursion Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7849) %, meaning that it created substantial loss on money invested by shareholders. Recursion Pharmaceuticals' management efficiency ratios could be used to measure how well Recursion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Recursion Pharmaceuticals' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 226.3 M in 2024, whereas Total Assets are likely to drop slightly above 520.4 M in 2024.
Recursion Pharmaceuticals currently holds 50.67 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. Recursion Pharmaceuticals has a current ratio of 5.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Recursion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Sharen PyatetskayaHepion Pharmaceuticals
N/A
Alexis AMRelay Therapeutics
52
Bernard JDSana Biotechnology
69
Launa AspesletHepion Pharmaceuticals
N/A
Henric BjarkeInozyme Pharma
57
Brittany MccleerySana Biotechnology
N/A
MS MBAInozyme Pharma
47
Julie MBADay One Biopharmaceuticals
42
Daren UreHepion Pharmaceuticals
N/A
Andreas BuschAbsci Corp
61
Nandan BSImmix Biopharma
62
CPA CPAAbsci Corp
65
BSc BScHepion Pharmaceuticals
66
Mike PreighDay One Biopharmaceuticals
N/A
Richard MDX4 Pharmaceuticals
61
Thomas CatinazzoRelay Therapeutics
48
Ibrahim MDEnveric Biosciences
55
Jack GoldAbsci Corp
N/A
Sean McClainAbsci Corp
34
Russell MSAcumen Pharmaceuticals
66
MBA IVEnveric Biosciences
68
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Recursion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 400 people. Recursion Pharmaceuticals (RXRX) is traded on NASDAQ Exchange in USA. It is located in 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 and employs 500 people. Recursion Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Recursion Pharmaceuticals Leadership Team

Elected by the shareholders, the Recursion Pharmaceuticals' board of directors comprises two types of representatives: Recursion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Recursion. The board's role is to monitor Recursion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Recursion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Recursion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Gibson, CEO CoFounder
Kevin Leggat, Vice Accounting
Janelle Gordon, Vice Operations
Ben Taylor, CFO UK
Shafique MD, Interim Officer
Nathan Hatfield, Chief Officer
Tina Larson, COO President
MBA JD, Chief Counsel
Michael Secora, Chief Officer
Kristen MBA, Chief Officer
David Hallett, Chief Officer
Jared Allenbach, Director Relations
Blake Borgeson, CoFounder Director
Ryan Kelly, Chief Officer
Benjamin MS, Chief Officer
Matthew Kinn, Chief Initiatives

Recursion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Recursion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.